GlobeNewsWire
14 Jun 2026, 09:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Celldex presented positive Phase 1 results for CDX-622, showing dose-dependent reductions in serum tryptase and mast cell depletion. — Successful early-stage human data for a novel mechanism is a primary catalyst for biotech valuation increases.
+0.60CDX-622 was reported to be well-tolerated across all dose levels in the healthy participant study. — Safety and tolerability are critical hurdles in Phase 1; positive results reduce the risk of early-stage clinical failure.
+0.40CDX-622 is currently being evaluated in a Phase 1b proof of mechanism study for mild to moderate asthma. — Advancement into a specific disease indication (asthma) creates a concrete path toward potential commercialization.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Celldex plans to initiate additional proof of concept studies for CDX-622 in allergic rhinitis and food allergy. — Expansion into multiple indications increases the total addressable market (TAM) for the candidate.
+0.20Which stocks this story touches
The company presented positive first-in-human Phase 1 results for its novel bispecific antibody CDX-622.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
19h ago
